Evidence map›Paper›PMID 35402633›Full record

ArticleMolecular therapy. Methods & clinical development2022

Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells.

Robin Nilson, Olivia Lübbers, Christoph Q Schmidt, Markus Rojewski, Philip Helge Zeplin, Wolfgang Funk, Hubert Schrezenmeier, Astrid Kritzinger, Stefan Kochanek, Lea Krutzke

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Robin NilsonDepartment of Gene Therapy, University of Ulm, Helmholtzstraße 8/1, 89081 Ulm, Baden-Württemberg, Germany.
Olivia LübbersDepartment of Gene Therapy, University of Ulm, Helmholtzstraße 8/1, 89081 Ulm, Baden-Württemberg, Germany.
Christoph Q SchmidtDepartment of Applied Immunology and Immunopharmacology, University Medical Center Ulm, Ulm, Germany.
Markus RojewskiInstitute for Transfusion Medicine, University Medical Center Ulm, Ulm, Germany.
Philip Helge ZeplinSchlosspark Klinik Ludwigsburg, Privatklinik für Plastische und Ästhetische Chirurgie, Ludwigsburg, Germany.
Wolfgang FunkSchönheitsklinik Dr. Funk, München, Germany.
Hubert SchrezenmeierInstitute for Transfusion Medicine, University Medical Center Ulm, Ulm, Germany.
Astrid KritzingerDepartment of Gene Therapy, University of Ulm, Helmholtzstraße 8/1, 89081 Ulm, Baden-Württemberg, Germany.
Stefan KochanekDepartment of Gene Therapy, University of Ulm, Helmholtzstraße 8/1, 89081 Ulm, Baden-Württemberg, Germany.
Lea KrutzkeDepartment of Gene Therapy, University of Ulm, Helmholtzstraße 8/1, 89081 Ulm, Baden-Württemberg, Germany.
Universität Ulm · DEGerman Red Cross · DESchlosspark-Klinik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In adenovirus type 5 (HAdV-5)-derived viral vectors, the fiber protein has been the preferred locale for modifications to alter the natural viral tropism. Hexon, the most abundant capsid protein, has rarely been used for retargeting purposes, likely because the insertion of larger targeting peptides into Hexon often interferes with the assembly of the viral capsid. We previously observed that positively charged molecules enhance the transduction of human multipotent mesenchymal stromal cells (hMSCs)-a cell type of significant interest for clinical development but inefficiently transduced by unmodified HAdV-5-based vectors. As efficient HAdV-5-mediated gene transfer would greatly increase the therapeutic potential of hMSCs, we tested the hypothesis that introducing positively charged amino acids into Hexon might enhance the transduction of hMSCs, enabling efficient expression of selected transgenes. From the constructs that could be rescued as functional virions, one (HAdV-5-HexPos3) showed striking transduction of hMSCs with up to 500-fold increased efficiency. Evaluation of the underlying mechanism identified heparan sulfate proteoglycans (HSPGs) to be essential for virus uptake by the cells. The ease and efficiency of transduction of hMSCs with this vector will facilitate the development of genetically modified hMSCs as therapeutic vehicles in different disciplines, including oncology or regenerative medicine.

Indexed as

adenovirusATMPscapsid modificationgene deliverygene therapyHAdV-5mesenchymal stem cellsmesenchymal stromal cellsnovel vector developmentviral vectors

Identifiers

PMID35402633
PMCPMC8956844
OpenAlexW4220717068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.